Daiichi Sankyo

AMRI and Biota strike development and manufacturing deal

Wednesday, April 18, 2012 09:44 AM

AMRI, a global contract research and manufacturing organization, was selected by Biota Holdings, an Australian anti-infective drug development company, to further develop and manufacture influenza antiviral CS8958 (laninamivir), a second-generation, long-acting neuraminidase inhibitor.

More... »

Syndax appoints Pappas to board of directors

Friday, April 6, 2012 03:26 PM

Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company based in Waltham, Mass., has added Arthur M. Pappas to the ranks of its board of directors.

More... »

Daiichi forms diabetes alliance with NGM Biopharma

Friday, March 30, 2012 03:07 PM

Tokyo-based Daiichi Sankyo has formed a partnership with San Francisco-based NGM Biopharmaceuticals to research and develop new treatments for diabetes.

More... »

Approved: Daiichi Sanyo’s edoxaban

Tuesday, April 26, 2011 01:28 PM

Japan-based Daiichi Sankyo has received marketing approval by the Japanese Ministry of Health, Labor and Welfare for its anticoagulant edoxaban, according to Pharma Times.  

More... »

Pieris and Daiichi Sankyo partner to develop Anticalin therapeutics

Tuesday, April 12, 2011 12:22 PM

Germany-based Pieris will collaborate with Japan-based Daiichi Sankyo and sign a licensed agreement under which Pieris will apply its Anticalin scaffold technology to discover novel Anticalins against two Daiichi Sankyo targets. As part of the agreement, Pieris will be responsible for early preclinical development for Anticalin drug candidates, and Daiichi Sankyo will assume responsibility for further development and marketing of the Anticalin compounds.

More... »

The CenterWatch Monthly April 2011

Friday, April 1, 2011 08:00 AM

Liability demands putting sites at risk

More... »

Daiichi Sankyo acquires Plexxikon

Tuesday, March 1, 2011 12:35 PM

In another sign that biotechnology companies with promising pipelines are able to forge rich buyout deals, Japanese pharmaceutical company Daiichi Sankyo has announced it will pay $805 million upfront and up to $130 million in near-term milestones for Plexxikon, a tiny oncology developer, according to Fierce Biotech.

More... »